Presidio Property Trust, Inc. (SQFT) - 10-Q Summary
Business Context and Reporting Period
Company: Presidio Property Trust, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2025
Business Overview: An internally managed REIT holding a diversified portfolio of office, industrial, retail, and triple-net leased model home properties. As of June 30, 2025, the portfolio included 10 commercial properties and 87 model homes.
Corporate Actions: The Company executed a 1-for-10 reverse stock split effective May 19, 2025, and completed a fixed-price tender offer in May 2025, repurchasing 214,412 shares of Series A Common Stock.
Key Financial Metrics (Six Months Ended June 30, 2025)
| Metric | Value |
|---|---|
| Total Revenue | $8.50 million |
| Net Loss (GAAP) | $(2.67) million |
| Net Loss Attributable to Common Stockholders | $(4.16) million |
| Net Operating Income (NOI) | $5.43 million |
| Adjusted NOI | $5.88 million |
| Cash, Cash Equivalents, and Restricted Cash | $7.29 million |
| Total Mortgage Notes Payable (Principal) | $95.42 million |
| Weighted Average Interest Rate | 5.90% |
| Dividends Paid (Series D Preferred) | $1.15 million |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased to $8.50 million from $9.38 million in the prior year period, driven by the sale of two commercial properties (Union Town Center and Research Parkway) in February 2025 and a reduction in model home rental income.
- Impairment Charges: The Company recorded significant non-cash impairment charges of $4.34 million, compared to $0.20 million in the prior year. This includes a $3.3 million charge related to the pending sale of the Dakota Center property and a $0.9 million charge for the Shea Center II property.
- Conduit Pharmaceuticals Investment: The Company sold its remaining shares of Conduit Pharmaceuticals (CDT) in May 2025. The loss on remeasurement of these securities was $0.18 million for the six months ended June 30, 2025, a significant improvement from the $13.89 million loss recorded in the same period in 2024.
- General and Administrative Expenses: G&A expenses decreased to $2.89 million from $4.29 million year-over-year, primarily due to the absence of one-time consulting fees and legal fees related to activist stockholder matters incurred in 2024.
- Debt Reduction: Total mortgage notes payable decreased to $95.42 million from $102.84 million, reflecting the payoff of debt associated with sold commercial properties.
Guidance, Outlook, and Risks
- Liquidity and Capital Resources: Management believes existing cash, operating cash flows, and refinancing capabilities will fund operations for at least the next 12 months. However, $24.4 million in principal payments are due in the remainder of 2025, and $19.7 million in 2026.
- Debt Maturities: Three commercial property loans totaling approximately $28.1 million mature within the next 12 months. The Company has finalized terms to refinance the Genesis Plaza and One Park Centre loans but is still exploring options for the Shea Center II loan maturing in January 2026.
- Default Status: The Company is in a maturity date default on the Dakota Center loan (approx. $9.1 million principal). The property is held for sale, and a third-party purchase offer of $5.125 million was approved in July 2025. The loan is non-recourse.
- Recent Financing: In July 2025, the Company completed a registered direct offering raising approximately $1.7 million in net proceeds. Additionally, the Company amended existing warrants to reduce the exercise price to $12.00 and extend the term to 2030.
- Dividends: No dividends were declared on Series A Common Stock. Monthly dividends on Series D Preferred Stock continue at $0.19531 per share.
- Risks: Key risks include the ability to refinance maturing debt on acceptable terms, the impact of interest rate increases, and the successful execution of the Dakota Center sale to settle the defaulted loan.
Investor Verification Checklist
- Dakota Center Sale: Verify the closing of the Dakota Center sale and the settlement of the defaulted non-recourse loan to confirm the elimination of the default status and associated interest penalties.
- Refinancing Progress: Monitor the status of refinancing for the Shea Center II loan (maturing Jan 2026) and other commercial loans maturing in 2025/2026 to assess refinancing risk.
- Model Home Portfolio: Review the occupancy and lease renewal rates for the 87 model homes, which represent a significant portion of the portfolio and are subject to short-term lease cycles.
- Conduit Warrants: Track the fair value of the remaining Conduit Pharmaceuticals warrants (approx. $7,700) and any potential future volatility in their valuation.
- Stock Repurchases: Confirm the remaining capacity under the stock repurchase program ($5.94 million for Common Stock and $3.63 million for Preferred Stock) and future buyback activity.